EBS
Price
$7.59
Change
-$0.04 (-0.52%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
404.4M
60 days until earnings call
VTRS
Price
$10.51
Change
+$0.18 (+1.74%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
12.24B
65 days until earnings call
Interact to see
Advertisement

EBS vs VTRS

Header iconEBS vs VTRS Comparison
Open Charts EBS vs VTRSBanner chart's image
Emergent Biosolutions
Price$7.59
Change-$0.04 (-0.52%)
Volume$13.29K
Capitalization404.4M
Viatris
Price$10.51
Change+$0.18 (+1.74%)
Volume$168.79K
Capitalization12.24B
EBS vs VTRS Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. VTRS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EBS: $7.63 vs. VTRS: $10.33)
Brand notoriety: EBS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 70% vs. VTRS: 83%
Market capitalization -- EBS: $404.4M vs. VTRS: $12.24B
EBS [@Pharmaceuticals: Generic] is valued at $404.4M. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.24B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 7 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 7 bullish, 4 bearish.
  • VTRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EBS is a better buy in the short-term than VTRS.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -9.06% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.2B) has a higher market cap than EBS($404M). VTRS has higher P/E ratio than EBS: VTRS (236.20) vs EBS (2.89). VTRS YTD gains are higher at: -13.813 vs. EBS (-20.188). VTRS has more cash in the bank: 406M vs. EBS (267M). EBS has less debt than VTRS: EBS (668M) vs VTRS (14.5B).
EBSVTRSEBS / VTRS
Capitalization404M12.2B3%
EBITDA344MN/A-
Gain YTD-20.188-13.813146%
P/E Ratio2.89236.201%
Revenue812MN/A-
Total Cash267M406M66%
Total Debt668M14.5B5%
FUNDAMENTALS RATINGS
EBS vs VTRS: Fundamental Ratings
EBS
VTRS
OUTLOOK RATING
1..100
7085
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
11
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3296
PRICE GROWTH RATING
1..100
3943
P/E GROWTH RATING
1..100
641
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (11) in the null industry is somewhat better than the same rating for EBS (54) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than EBS’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

EBS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for VTRS (96) in the null industry. This means that EBS’s stock grew somewhat faster than VTRS’s over the last 12 months.

EBS's Price Growth Rating (39) in the Biotechnology industry is in the same range as VTRS (43) in the null industry. This means that EBS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for EBS (64) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 4 days ago
68%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
51%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCSGX15.240.17
+1.13%
PACE Small/Medium Co Growth Equity P
VESMX19.800.19
+0.97%
VELA Small Cap I
SMYIX27.920.25
+0.90%
Franklin Global Equity I
WFINX59.150.50
+0.85%
Allspring Index C
RDCEX15.300.09
+0.59%
Columbia Disciplined Core C

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-2.55%
SIGA - EBS
43%
Loosely correlated
-1.39%
VTRS - EBS
42%
Loosely correlated
-2.09%
ELAN - EBS
39%
Loosely correlated
+0.69%
HKMPF - EBS
34%
Loosely correlated
N/A
PAHC - EBS
34%
Loosely correlated
+2.29%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-2.09%
ELAN - VTRS
53%
Loosely correlated
+0.69%
ZTS - VTRS
46%
Loosely correlated
+0.51%
AMRX - VTRS
44%
Loosely correlated
+0.10%
EBS - VTRS
43%
Loosely correlated
-2.55%
COLL - VTRS
37%
Loosely correlated
-0.91%
More